The effect of sample size on polygenic hazard models for prostate cancer.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
10
2019
accepted:
22
05
2020
revised:
27
02
2020
pubmed:
10
6
2020
medline:
9
6
2021
entrez:
10
6
2020
Statut:
ppublish
Résumé
We determined the effect of sample size on performance of polygenic hazard score (PHS) models in prostate cancer. Age and genotypes were obtained for 40,861 men from the PRACTICAL consortium. The dataset included 201,590 SNPs per subject, and was split into training and testing sets. Established-SNP models considered 65 SNPs that had been previously associated with prostate cancer. Discovery-SNP models used stepwise selection to identify new SNPs. The performance of each PHS model was calculated for random sizes of the training set. The performance of a representative Established-SNP model was estimated for random sizes of the testing set. Mean HR
Identifiants
pubmed: 32514134
doi: 10.1038/s41431-020-0664-2
pii: 10.1038/s41431-020-0664-2
pmc: PMC7608255
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1467-1475Subventions
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NIBIB NIH HHS
ID : K08 EB026503
Pays : United States
Organisme : Prostate Cancer UK
ID : PG13-001
Pays : United Kingdom
Références
Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D’Amato M, et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol. 2011;60:21–8.
doi: 10.1016/j.eururo.2011.01.017
Machiela MJ, Chen C, Chanock SJ, Hunter DJ, Kraft P. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol. 2011;35:506–14.
pubmed: 21618606
pmcid: 21618606
Vassy JL, Hivert MF, Porneala B, Dauriz M, Florez JC, Dupuis J, et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes. 2014;63:2172–82.
doi: 10.2337/db13-1663
Marden JR, Walter S, Tchetgen Tchetgen EJ, Kawachi I, Glymour MM. Validation of a polygenic risk score for dementia in black and white individuals. Brain Behav. 2014;4:687–97.
doi: 10.1002/brb3.248
Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135:2091–101.
doi: 10.1161/CIRCULATIONAHA.116.024436
Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med. 2017;14:1–17.
doi: 10.1371/journal.pmed.1002258
Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:1–7.
Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17:392–406.
doi: 10.1038/nrg.2016.27
Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–90.
doi: 10.1038/s41576-018-0018-x
Eeles RA, Olama AAAl, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45:385–91.
doi: 10.1038/ng.2560
Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014;15:1109–18.
doi: 10.1016/S1470-2045(14)70361-4
Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL consortium. Cancer Epidemiol Biomarkers Prev. 2008;17:2052–61.
doi: 10.1158/1055-9965.EPI-08-0317
Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, et al. Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate. 2015;75:1467–74.
doi: 10.1002/pros.23037
Minh-Phuong H-L, Chieh Fan C, Karunamuni R, Martinez ME, Eeles RA, Kote-Jarai Z, et al. Polygenic hazard score predicts aggressive and fatal prostate cancer in multi-ethnic populations. medRxiv. 2019. https://doi.org/10.1101/19012237 .
Therneau TM, Li H. Computing the Cox Model for case cohort designs. Lifetime Data Anal. 1999;5:99–112.
doi: 10.1023/A:1009691327335